| Title |
Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults
|
|---|---|
| Published in |
Current Oncology Reports, May 2016
|
| DOI | 10.1007/s11912-016-0519-8 |
| Pubmed ID | |
| Authors |
Aharon Ronson, Ariella Tvito, Jacob M. Rowe |
| Abstract |
Patients with relapsed and refractory acute lymphoblastic leukemia (ALL) have a dismal prognosis with less than 10 % of patients surviving 5 years. Most such patients cannot be rescued with currently available therapies, whatever the initial treatment they receive. Therefore, there is an urgent need for novel treatment options. Fortunately, over the past several years, an improved understanding of the biology of the disease has allowed the identification of rational molecular targets for therapeutic endeavors and the emergence of novel therapies has sparked great interest. This review will discuss the current treatment landscape for adult patients with relapsed and/or refractory ALL. |
Mendeley readers
The data shown below were compiled from readership statistics for 91 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 1% |
| Unknown | 90 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 15% |
| Student > Ph. D. Student | 13 | 14% |
| Student > Postgraduate | 11 | 12% |
| Student > Bachelor | 10 | 11% |
| Student > Master | 8 | 9% |
| Other | 16 | 18% |
| Unknown | 19 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 33 | 36% |
| Biochemistry, Genetics and Molecular Biology | 10 | 11% |
| Agricultural and Biological Sciences | 10 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 10% |
| Immunology and Microbiology | 3 | 3% |
| Other | 5 | 5% |
| Unknown | 21 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 467. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 December 2018.
All research outputs
#47,576
of 22,962,258 outputs
Outputs from Current Oncology Reports
#2
of 887 outputs
Outputs of similar age
#1,154
of 333,640 outputs
Outputs of similar age from Current Oncology Reports
#1
of 15 outputs
Altmetric has tracked 22,962,258 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 887 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.8. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 333,640 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.